AeroRx raises $21 million to push COPD therapy into late-stage development

US biotech AeroRx Therapeutics has secured $21 million in series A financing to advance its lead program, AERO-007, into Phase IIb testing in chronic obstructive pulmonary disease. The round was led by Avalon BioVentures, with support from Correlation Ventures and Alexandria Venture Investments.

The company said results from a Phase IIa trial showed the nebulized LABA/LAMA combination was well tolerated and provided sustained bronchodilation over 24 hours at both low and high doses. AeroRx chief executive Ahmet Tutuncu said the financing puts the company in position to begin dose-optimization and prepare for late-stage, NDA-enabling studies.

Avalon BioVentures managing partner Jay Lichter noted that while inhaled dual bronchodilation is standard care, poor adherence remains widespread due to difficulties with inhaler technique. AeroRx believes nebulized delivery may improve dosing consistency for patients who struggle with handheld devices.